Mdm2 and MDMX are two structurally related p53-binding proteins which show the highest level of sequence similarity in the N-terminal p53-binding domains. Apart from its ability to inhibit p53 mediated transcription, a feature it shares with mdm2, very little is known about the physiological functions of MDMX. It is clearly distinct from mdm2 since its expression appears not to be regulated by p53 and it cannot compensate for lack of mdm2 in early development. We present data on the structural similarity between the p53 binding pockets of mdm2 and MDMX using p53-and phage-selected peptides. From the results we conclude that our recently devised innovative approach to reverse the mdm2-mediated inhibition of p53's transactivation function in vivo would probably target MDMX as well. Strategies for selectively targeting mdm2 and MDMX are suggested and a possible mechanism for regulating the p53-mdm2/MDMX interactions by protein phosphorylation is discussed.
Introduction
Recent ®ndings that mdm2 is a key regulator of the stability of p53 has sparked o an increased interest in this important protein-protein interaction (Haupt et al., 1997; Kubbutat et al., 1997; Midgley and Lane, 1997) .
Mdm2 was ®rst described as an ampli®ed gene on a mouse double minute chromosome in spontaneously transformed 3T3 cells (3T3DM cell line, Cahilly Snyder et al., 1987) and found to have oncogenic potential (Fakharzadeh et al., 1991) . Mdm2 gained reputation after it was identi®ed as a p53 binding protein (Barak and Oren, 1992 ) and inhibitor of p53-mediated transactivation (Momand et al., 1992) .
A possible implication in human oncogenesis was revealed by ®ndings that in many human sarcomas mdm2 is overexpressed alongside with functional p53. It is thought that the p53 tumor suppressor function in these tumors is restrained by binding of mdm2 to an N-terminal amphipathic helix on p53 preventing basic transcription factors from binding to the same site. If this was true then any treatment that prevents mdm2 binding to p53 should suddenly release high levels of transcriptionally active p53. This in turn would block tumor growth by inducing cell cycle arrest and/or apoptosis. That this approach might be feasible has been demonstrated in tissue culture. A monoclonal anti-mdm2 antibody microinjected into the nuclei of tumor cells was able to activate p53 transactivation function (Blaydes et al., 1997) . It is known that this antibody can prevent or interrupt the p53-mdm2 binding since it has its epitope in the p53 binding pocket of mdm2 (BoÈ ttger et al., 1997a) .
Recently we have devised an innovative approach to reverse the mdm2-mediated inhibition of p53's transactivation function in vivo (BoÈ ttger et al., 1997b) . It is based on the design of a miniprotein called SuperTip (Thioredoxin insert protein) and consists of a phage library-selected mdm2-binding peptide displayed on the surface of bacterial thioredoxin. Expressing SuperTip in cells with low levels of wildtype p53 leads to accumulation of p53 protein accompanied by activation of a p53-responsive reporter gene and growth inhibition. This proves that SuperTip eciently targets endogenous mdm2 thereby interfering with its well established eects on p53, namely p53 degradation and inhibition of transactivation function.
A structural (and functional ?) analogue of mdm2 called MDMX has been described recently (Shvarts et al., 1996 (Shvarts et al., , 1997 . Similarly to mdm2 it binds to p53 and blocks its transactivation of a p53-responsive reporter gene. In contrast to mdm2 its expression seems not to be regulated by p53 and MDMX levels do not change after UV irradiation of cells. Any involvement in targeting p53 for degradation has not been described for MDMX yet. MDMX can obviously not compensate for lack of mdm2 function during early stages of embryonic development as mdm2 knockout experiments suggest (Jones et al., 1995; Montes de Oca Luna et al., 1995) .
From our current knowledge a dierent physiological role of MDMX compared to mdm2 can be assumed. Therefore it is desirable to dissect the actions of these two proteins on p53 by selectively targeting mdm2's and MDMX's p53 binding pocket.
Based on our intrinsic knowledge of the mdm2-p53 interface and the availability of structurally related but clearly distinct peptide variants that bind to mdm2 we compare here the structural requirements for mdm2 and MDMX binding to p53. As the interacting sites between p53 and mdm2/MDMX seem to be structurally conserved we had to ask if our miniprotein approach would aect MDMX functions as well. Finally we show how phosphorylation of a p53 peptide aects its ability to block the p53-mdm2/ MDMX interactions in vitro.
Results

Display of mdm2 and MDMX on ®lamentous phage
N-terminal fragments of human mdm2 (a.a. 1 ± 183) and MDMX (a.a. 1 ± 185) comprising the p53 binding domain were cloned into phagemid vectors (pHEN1 and pCantab6) in frame with the gIII protein and expressed on the surface of ®lamentous phage.
Protein display was monitored in phage ELISAs where mdm2 and MDMX speci®c antibodies were used to capture recombinant phage. A collection of monoclonal antibodies speci®c for the N-terminus of mdm2 (4B2, 3G5, SMP14, S1/8, Figure 1a ,c) was able to detect phage displayed mdm2 but not MDMX (Figure 1b,d) , whereas a C-terminal mdm2 antibody (CT12) and an irrelevant antibody (DO-1, anti-p53) were negative for both proteins. Evidence for phage Figure 1 Expression of human mdm2 and MDMX on ®lamentous phage. N-terminal fragments of mdm2 (a.a. 1 ± 183) and MDMX (a.a. 1 ± 185) were cloned into phagemid vectors pHEN1 and pCantab6 and displayed on ®lamentous phage. Mdm2 phage (a,c) but not MDMX phage (b,d) were recognized by anti-mdm2 antibodies 4B2, 3G5, SMP14 and S1/8 (CT12 could not bind since it is speci®c for the C terminus of mdm2). On the other hand, an MDMX speci®c antiserum only pulls down MDMX displaying phage (e). A c-myc tag sequence between the mdm2 (MDMX) and gpIII was targeted by 9E10 and the major coat protein of the phage, gpVIII, by FE2. DO-1, an anti-p53 antibody, served as negative control display of MDMX was provided by a rabbit anti-MDMX antiserum (Figure 1e ). The expression of a cmyc tag sequence at the C-terminus of the cloned protein was detected by antibody 9E10 and the presence of phage particles by a monoclonal antiphage pVIII antibody (FE2).
Once the speci®c expression of mdm2 and MDMX had been established we asked whether phage displayed mdm2 is still able to adopt the native conformation for binding of p53-and phage selected peptides (BoÈ ttger et al., 1996 (BoÈ ttger et al., , 1997a . Surprisingly, hardly any speci®c phage binding could be detected (shown left in Figure   Figure 2 Binding of mdm2-and MDMX-phage to p53-and phage-derived peptides. (a) Mdm2 and MDMX expressed on phage are equally able to bind to peptide 12/1 which had been selected for strong binding to mdm2 by phage peptide library screening (BoÈ ttger et al., 1996) . An ecient binding is absolutely dependent on reducing conditions (10 mM DTT) as it had been shown before for binding of solid phase mdm2 to p53 and peptides (BoÈ ttger et al., 1997a) . pCantab6-CIP-Trx phage express an unrelated protein and were used as negative control. (b) MDMX reveals a very similar ®ne speci®city compared to mdm2 towards peptides selected from phage peptide libraries for speci®c mdm2 binding (12/1, 12/2, 12/5, 15/1, 15/5, BB3). Alanine substitution of residues essential for mdm2 binding abolish binding of mdm2 and MDMX likewise (12/1_Ala_PEN compared to 12/1_PEN; PEN=penetratin). Both, mdm2 and MDMX bind to a p53 peptide (p53-wt) which contains the known mdm2 binding site on p53 (Picksley et al., 1994) . Peptides 84 and 90 and phage pool pCantab6-CIP-Trx were used as negative controls
Comparison of the p53-mdm2 and -MDMX interfaces V Bo Èttger et al 2a for phage derived peptide 12/1). From our detailed biochemical analysis of the mdm2-p53 interaction we knew that solid phase mdm2 is highly dependent on reducing conditions for ecient p53 (and peptide phage) binding (BoÈ ttger et al., 1997a) . We therefore included DTT in our assays and indeed got a dramatic increase in binding of phage displayed mdm2 towards the biotinylated peptides immobilized on steptavidin plates (Figure 2a , 10 mM DTT). On the other hand, the presence of DTT reduced non-speci®c binding of unrelated phage to mdm2-binding peptides and mdm2-phage binding to unrelated peptides (not shown). Figure 2a also reveals that MDMX itself is able to bind to peptide 12/1 which originally had been selected from a 12mer peptide phage display library for strong binding to mdm2. This binding seems to be negatively aected by oxidation too. Now the whole range of phage derived mdm2-binding peptides as well as a p53 wildtype peptide (identical in sequence to the mdm2 recognition site on p53) were tested for MDMX binding. It turned out that all mdm2 binding peptides were recognized by MDMX (Figure 2b) . A modi®ed 12/1 sequence which had the amino acids essential for mdm2 binding (BoÈ ttger et al., 1997a; Kussie et al., 1996) replaced by alanines was completely ignored by mdm2 and MDMX.
Binding of soluble MDMX protein to p53 and phage derived peptides To see whether the observed binding characteristics of phage displayed mdm2 and MDMX are similar to those of the soluble proteins and for a more detailed comparative analysis MDMX was expressed as GST fusion protein in the same way as it had been done for mdm2 (BoÈ ttger et al., 1996) .
We ®rst looked at the binding of GST-mdm2 (1 ± 188) and GST-MDMX (1 ± 185) to solid phase bound peptides and to full length p53. Both proteins are very similar in their ability to bind to decreasing concentrations of full length p53 (Figure 3b ) and p53 wildtype peptide as well as to (phage)peptides 12/1, 12/2 and 15/ 5 (Figure 3a) . A weaker binding is seen for MDMX towards peptides 12/5 and the 15mer peptides 15/1 and BB3. The alanine substituted 12/1 peptide is not being recognized by either protein as had been shown for phage binding before (Figure 2b) .
Secondly, we examined how our peptides would perform as solution phase antagonists of the p53-MDMX interaction in vitro and how this would compare to the already established activities of these peptides in p53-mdm2 inhibition ELISAs. The results are shown in Table 1 . The following points can be emphasized: (1) the eciency of the peptides acting as Figure 3 Comparative binding of GST-mdm2 and GST-MDMX to p53 and mdm2-binding peptides. Mdm2 and MDMX fusion proteins were oered to wells coated with decreasing concentrations of p53 (b) or biotinylated p53-and phage derived peptides (a). A very similar binding behaviour was observed to p53, to a p53 peptide containing the mdm2 binding site on p53 and to (phage) peptides 12/1, 12/2 and 15/5. Preferential binding of mdm2 was seen to peptides 12/5, BB3 and 15/1. Both, mdm2 and MDMX are unable to recognize a modi®ed 12/1 peptide which had its critical amino acids for mdm2 binding replaced by alanines (a, bottom right). The binding of mdm2 and MDMX to p53 is eectively inhibited by SuperTip protein (c), which is peptide 12/1 sequence inserted into the active side loop of bacterial thioredoxin. This suggests that the in vivo miniprotein approach described in BoÈ ttger et al. (1997b) would probably target intracellular MDMX
Comparison of the p53-mdm2 and -MDMX interfaces V Bo Èttger et al inhibitors are much more heterogeneous compared to their binding behaviour (peptides on solid phase, Figure 3a) ; (2) all peptides tested are less able to compete with MDMX for p53 binding; (3) the 15mer peptides show a clear preference for mdm2, especially BB3; (4) peptide 12/1 is the most potent in vitro inhibitor of both, mdm2 and MDMX binding to p53.
Since 12/1 is the active core sequence in our SuperTip we asked whether it would retain its strong anity when in context with thioredoxin not only to mdm2 (BoÈ ttger et al., 1997b) but also to MDMX. To that end, the SuperTip protein was preincubated in decreasing concentrations with mdm2 or MDMX and than oered to solid phase p53. Figure 3c shows that both mdm2 and MDMX are eciently prevented by SuperTip from binding to p53. The dierence between mdm2 and MDMX is similar to that shown for peptide 12/1 in the p53-mdm2 inhibition ELISAs (Table 1) .
BIAcore analysis
The interaction between mdm2 (1 ± 188) or MDMX (1 ± 185) with p53-and phage-derived peptides (ligands) was monitored in real time on a BIAcore 2000 system (Biacore AB, Sweden) using biotinylated ligands bound to a streptavidin sensor chip. The response curves obtained during (ascending part of curve=association kinetics) and after injection (descending part of curve=dissociation kinetics) of mdm2 ( Comparison of the p53-mdm2 and -MDMX interfaces V Bo Èttger et al bound to the peptides during time of injection and is directly proportional to the association rate constant k a of the peptide-protein interaction. The following conclusions can be drawn: The amount of mdm2 bound to peptide 12/1 at the end of the protein injection clearly excels that which is bound to p53 wildtype peptide (wt), with peptide 12/5 being the weakest interaction partner. More mdm2 than MDMX associates with each particular peptide (RU mdm2_RU MDMX: 12/1 4000_2700; wt 2600_2200; 12/5 1400_600), (Figure 4a and b) . The relative ranking of the association rates for mdm2 to peptides 12/1, BB3 and wt is 12/14BB34wt and for MDMX 12/ 14BB3=wt. Again more mdm2 than MDMX binds to peptide 12/1 (7000_3700), BB3 (5000_1800) and wt (2300_1750) (Figure 4c and d) .
These qualitative interpretations of the real time interaction between mdm2/MDMX and dierent peptides correspond very well to the quantitative peptide inhibition data in Table 1 . On the other hand these BIAcore data describe the dynamics of the peptide-protein interaction completely (complex formation and decay) whereas ELISA binding and inhibition assays can only produce a snapshot of one time point during complex dissociation. However, a reliable quantitative analysis (calculation of apparent rate and anity constants) of the response curves in Figure 4 is not yet possible since these data do not ®t a simple one to one interaction kinetics (BIAevaluation 3.0 software). Further BIAcore experiments have to be conducted with much decreased ligand concentration and varying analyte amount and¯ow rate to assess which higher order kinetics describes the mdm2/MDMX-peptide interaction best or whether experimental artefacts conceal a simple one to one binding.
In vitro binding assay with full length MDMX and MDM2
So far, we had used the N-terminal 185 or 188 amino acids of MDMX or mdm2, respectively to study the p53-MDMX and p53-mdm2 interactions. We now investigated whether the mdm2 binding peptides would inhibit the association of p53 with full length mdm2 and MDMX in a similar manner. Therefore, three of the peptides were selected and in dierent concentrations incubated with GST-MDMX or GSTmdm2. Subsequently, in vitro translated and 35 S labelled, p53 was added to compete with the peptide/ MDMX or peptide/mdm2 association.
As shown in Figure 5 , the ability of the dierent peptides to compete with p53-binding to MDMX and mdm2 is very similar. Peptide wt-CON competes most eciently with p53 for binding to both MDMX (Figure 5a , panel 2) and mdm2 ( Figure 5b, panel 2) . On the other hand, peptide 12/5 is hardly able to prevent binding of p53 to MDMX (Figure 5a, panel  3) , and is very inecient in blocking the association of p53 with mdm2 ( Figure 5b, panel 3) . Both peptide BB3 and the wildtype sequence peptide (wt) have intermediate ability to compete with full length p53 for binding to MDMX, while BB3 is almost equally ecient as wt-CON in blocking the association between p53 and mdm2 ( Figure 5b , compare panels 2 and 4).
Although the competition pattern is very similar for MDMX and mdm2 (compare Figure 5a and b) , the IC 50 values are dierent. In Table 1 we show the IC 50 values for MDMX and mdm2. To reduce the association between p53 and mdm2 by 50%, much lower concentrations of the peptides are required than for the binding to MDMX. Especially the dierence in the IC 50 values for peptide 12/5 is very intriguing (8.2 and more than 100 mM for mdm2 and MDMX, respectively), while the dierence for the wildtype peptide is very small.
A possible mechanism to modulate the p53-mdm2 interaction Testing peptides that ®t into the p53 binding pocket on mdm2 for their capacity to inhibit the p53-mdm2 interaction has previously provided us with enormous Figure 5 Interference of peptide inhibitors with the binding of p53 to full length mdm2 and MDMX. Full length GST-mdm2 and GST-MDMX bound to Glutathione Sepharose beads were preincubated with dierent concentrations of peptides wt, wt-CON, 12/5 or BB3. Subsequently, in vitro translated 35 S labelled p53 was added and the amount of bound p53 was analysed. The ability of the peptides to inhibit the binding of p53 to full-length MDMX (a) and mdm2 (b) is similar to that seen for N-terminal MDMX/mdm2. The calculated IC 50 values from these experiments are shown in Table 1 Comparison of the p53-mdm2 and -MDMX interfaces V Bo Èttger et al insights into the structural requirements for the mdm2 binding site on p53 (BoÈ ttger et al., 1996 (BoÈ ttger et al., , 1997a . One of the inhibiting peptides was an optimised p53 wildtype sequence with two amino acid substitutions which had been strongly selected for by phage display (BoÈ ttger et al., 1996) . The sequence was Q-P-T-F-S-D-Y-W-K-L-L-P (the bold amino acids are deviations from the wildtype Figure 6 (a) In¯uence of amino acid substitutions on the inhibitory potential of an optimized p53 wildtype peptide (QPTFSDYWKLLP). Amino acids in bold are deviations from the p53 wildtype sequence and have been introduced to make this peptide a much better inhibitor of the mdm2-p53 interaction (BoÈ ttger et al., 1996) . Each amino acid in this peptide was replaced by any of the other 19 amino acids and the eect of these changes was measured in a p53(peptide)-mdm2 inhibition ELISA. The number of amino acids which can replace the original amino acid in a given position without aecting the inhibitory potential of the peptide is shown. For example, threonine in position 3 can only be replaced by one other amino acid whereas position 5 accepts 18 dierent amino acid exchanges. ELISA assays for binding of GST-mdm2 (1 ± 188) and GST-MDMX (1 ± 185) (b,f) or binding of anti-p53 antibodies Bp 53.19 (c), DO-2 (d) and DO-1 (e) to p53 coated plates in the presence of p53 derived peptides (sequence shown on top left panel), unphosphorylated (wt), phosphorylated at S 15 (S15), T 18 (T18) or S 20 (S20). The wildtype peptide inhibits all interactions in a concentration dependent manner and variations from this inhibition by phosphorylation of distinct amino acids become obvious by shifts in the inhibition curves Figure  6a ). This drew our attention to the fact that T 18 and S 20 could potentially be phosphorylation sites on the p53 N-terminus, although kinases to phosphorylate these positions have so far not been described. We therefore tested phosphopeptides, with phosphorylated T Consequently we then used the phosphopeptides to challenge the binding of MDMX to p53. The picture we got (Figure 6f ) is very similar to that seen for mdm2. The peptide phosphorylated at T 18 is about 16 times less ecient in inhibiting the MDMX-p53 interaction compared to the p53 wt peptide and the S 15 and S 20 phosphorylated peptides. We intrinsically controlled the quality of the phosphopeptides in this experiment by testing their capacity to inhibit the interaction of p53 with three antibodies, whose epitopes on the p53 N-terminus are well de®ned (Stephen et al., 1995 . All three phosphopeptides and the p53 wildtype peptide are equally able to inhibit the antibody-p53 interaction (Figure 6c ). DO-2 binds p53 at a region around S
15
. Consequently phosphorylation at this position abolishes the ability of the phosphopeptide to inhibit the interaction of DO-2 with its epitope on p53 (Figure 6d ). Phosphorylation at T 18 or S 20 has no eect. Finally, DO-1 binds p53 very closely to the mdm2 binding site, the core epitope comprising S 20 to L
25
. Phosphorylation at S 20 completely abolishes DO-1 binding to p53 whereas S 15 phosphorylation has no eect and T 18 phosphorylation diminishes the anity of the antibody for p53 (Figure 6e ). In these purely biochemical assays we can predict that phosphorylation at T 18 alone would decrease the anity of p53 for mdm2 considerably. In a physiological system, such a decrease in anity of p53 for mdm2 would have a profound impact on the interaction. These data strongly imply that phosphorylation at T 18 could be considered as a candidate mechanism to trigger the release of p53 from mdm2.
Discussion
The aim of this study was to investigate the binding speci®city of MDMX to p53 in comparison with the well established mdm2-p53 interaction. To this end we constructed a genetic package enabling us to express human mdm2 and MDMX on the surface of ®lamentous phage. Phage display has proved to be a very powerful and elegant method for constructing and screening vast libraries of random peptides, antibodies and protein fragments as well as expressing and selecting proteins and protein domains. The selective enrichment of phage carrying a desired phenotype is made possible by the physical link of the selected trait and the genotype coding for it in one infectious particle.
Here we show that both mdm2 and MDMX can be expressed on phage in a native conformation. First we tried to display full length proteins but realized that they get only poorly expressed on phage. This is partly due to protein degradation at the N-terminus of mdm2/MDMX (data not shown). It also seems as if only a small amount of the produced mdm2/MDMX is accessible for integration into the phage coat since both proteins are notorious for their insolubility in bacteria. Therefore we decided to deal only with N-terminal fragments which contain the entire p53 binding domain. These domains were eciently expressed on phage and not prone to degradation. The ®nding that phage displayed mdm2 and MDMX are entirely dependent on a reducing environment (DTT) to bind to p53(peptide) con®rmed our earlier results with soluble proteins. It emphasizes the need for an intrinsic knowledge of this speci®c protein-protein interaction to get these proteins displayed in an active state. It is tempting to speculate here that the interaction between mdm2 and p53 in vivo could be aected by oxidative stress.
We were quite surprised to see that our collection of phage peptides which had been selected for mdm2 binding were recognized by MDMX as well. One might say that this was to be expected since most of the amino acids shown to be involved in p53 binding are conserved in MDMX (71% identity; 93% similarity). On the other hand the amino acid sequences of mdm2 and MDMX in the entire p53 binding region seem to be dierent enough (66% similarity) to exhibit dierent ®ne speci®cities at least towards the arti®cial phage peptide sequences even though dierences in binding to the native target (p53 peptide) might not show up or even exist. The strength of phage library selected peptides to reveal dierences in ®ne speci®cities of antibodies (originating from the same B cell progenitor and binding to the same native epitope) with very similar sequences has been demonstrated before (BoÈ ttger et al., 1995) . We can therefore assume that the conformation of the p53 binding pockets on mdm2 and MDMX are almost identical. We can of course not exclude that selecting additional phage peptides with mdm2 and in particular with MDMX might produce some mimotopes exclusively recognized by one or the other protein. The clear dierences in the inhibitory potential of some peptides (especially BB3, see Table  1 ) point in this direction.
We have recently designed a miniprotein that is able to target mdm2 in living cells thereby preventing it from exerting its inhibiting eect on p53's transactivation function. Since the active principle on this miniprotein, called SuperTip, is based on the phage peptide sequence 12/1 which is bound by MDMX as well (Table 1) we have to assume that SuperTip can also target MDMX although less eciently. Therefore SuperTip cannot be used to dissect possible dierences in downstream events once mdm2 or MDMX have bound to p53. A BB3-based SuperTip construct which should preferentially but not exclusively target mdm2 could address this problem. An even better alternative is available in form of the mdm2 speci®c antibody 3G5 which has its epitope at the edge of the p53 binding pocket on mdm2. Microinjected into cells this antibody has been shown to interfere with the mdm2-p53 interaction pretty much in the same way as SuperTip does. Since it does not bind to MDMX (because the minimal epitope sequence de®ned for mdm2 by phage display, LY(X)E, is not completely present on MDMX), see Figure 1 , it should only inhibit mdm2's action on p53. Parallel treatment of cells expressing wildtype p53, mdm2 and MDMX with SuperTip 12/1, or SuperTip BB3 or an 3G5 single chain antibody (transfection or microinjection) might reveal dierent consequences of the selective abrogation of mdm2-p53 and MDMXp53 interactions.
Recent discoveries have shown that agents able to block the p53-mdm2 interaction like SuperTip and the antibody 3G5 can increase p53 protein levels and induce its transcriptional activity. By doing this these agents mimic the cellular p53 response to genotoxic insults. The question arises if the accumulation of p53 after DNA damage is primarily caused by release of p53 from its constraint by mdm2 and how this release could be mediated. The N terminus of p53 which harbours the mdm2 binding site is targeted by a number of cellular kinases some of which are induced by stress or DNA damage (reviewed by Meek et al., 1997) .
Using phosphopeptides we investigated how phosphorylation of amino acids within or close to the mdm2 binding site on p53 could aect the interaction of the two proteins. We show here that phosphorylation of T 18 on p53 would most likely have a profound inhibitory eect on the interaction between mdm2 and p53, whereas phosphorylation at S 20 or S 15 would not. Kinases that phosphorylate T 18 have not been described yet. S 15 phosphorylation, on the other hand, has been found to be carried out by DNA-PK in vitro (Lees-Miller et al., 1992) . DNA PK is activated after binding to DNA double strand breaks or nicks (Gottlieb and Jackson, 1993) . Recently it has been described by Shieh et al., (1997) that p53 phosphorylation at S 15 in conjunction with S 37 by DNA-PK impairs mdm2's ability to bind to p53 and to inhibit p53-dependent transactivation in vitro. The same group states that this is most likely due to changes in the tertiary structure of the phosphorylated p53. Whilst our here described peptide approach addresses mainly the eects of changes in the primary structure of p53 on its binding to mdm2 a recent report by Mayo et al. (1997) describes that phosphorylation of p53 by DNA-PK had no eect on its ability to interact with mdm2. The same group shows, on the other hand, that DNA-PK is able to phosphorylate S 17 on human mdm2 which causes a decrease in its ability to interact with p53.
In scid cells, which are defective in DNA-PKcs (Fried et al., 1996; Rathmell et al., 1997) , the p53 response to DNA damage seems to be completely intact pointing to the possible involvement of other kinases. The discovery of a kinase which phosphorylates T 18 has still to be awaited. We also cannot exclude that phosphorylation at S 6 and S 9 of p53 which can be carried out by Casein kinase I related enzymes (Knippschild et al., 1996; Milne et al., 1992) , would have an eect on the p53-mdm2 interaction. Interestingly, p53 phosphorylation would have similar consequences on its ability to bind to both mdm2 and MDMX, here suggesting similarities in regulation of the two interactions.
In summary, on a biochemical level, the interactions between p53 and both its transcriptional inhibitors mdm2 and MDMX are very conserved. The dierential elucidation of the biological functions of both proteins should therefore be awaited with great interest. Employing the here suggested inhibitors that would speci®cally target mdm2 as well as creating speci®c MDMX inhibiting agents could surely contribute enormously to this quest.
Materials and methods
Human mdm2 and MDMX constructs
Expression of mdm2 and MDMX on ®lamentous phage: cDNA fragments comprising the N-terminal nucleotide sequence 1 ± 549 of human mdm2 (for amino acids 1 ± 183) and 1 ± 555 of human MDMX (for amino acids 1 ± 185) were ampli®ed by PCR using extended primers which insert S®I and NotI sites at the 5' and 3', ends, respectively: S®I-mdm2 (07511): GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC ATG TGC AAT ACC AAC ATG TCT; NotI-mdm2_183 (07890): GAG TCA TTC TGC GGC CGC GCG TTT TCT TTG TCG TTC ACC; S®I-MDMX (07734): GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC ATG ACA TCA TTT TCC ACC TCT; NotI-MDMX_185 (07891): GAG TCA TTC TGC GGC CGC CCT AGA TGT TTC ATC TTG GGC. Puri®ed PCR products were digested with S®I and NotI and ligated into (S®I and NotI cut and dephosphorylated) phagemid vectors pHEN1 (Hoogenboom et al., 1991) and pCantab6 (McCaerty et al., 1994) . The constructs were transformed into E. coli TG1 cells and single clones were picked for phage rescue (Hoogenboom et al., 1991) using M13KO7 helper phage. Phage particles were puri®ed from the supernatant of overnight cultures (grown at room temperature) with Polyethylene glycol (PEG) and used for phage ELISA.
Expression of GST-MDMX: An MDMX cDNA fragment (1 ± 555) was PCR ampli®ed with primers that introduce a BamHI site (5' end) and an EcoRI site (3' end): BamHI-MDMX: CGG GAT CCA TGA CAT CAT TTT CCA CCT CT; EcoRI-MDMX_185: CGG AAT TCG CCT AGA TGT TTC ATC TTG. An mdm2 fragment in vector pGEX-2T (BoÈ ttger et al., 1996) was removed by BamHI/ EcoRI digest and replaced by the MDMX fragment. IPTG induced GST-MDMX_185 was puri®ed on Glutathione sepharose as described (BoÈ ttger et al., 1996) .
ELISAs
Phage ELISAs:Antibody-based ELISA (Figure 1 ) Monoclonal antibodies (hybridoma supernatant diluted 1 : 5)
Comparison of the p53-mdm2 and -MDMX interfaces V Bo Èttger et al were immobilized in ELISA plate wells precoated with anti-mouse antibodies (Dako Z259 1 : 1000 in PBS). Puri®ed phage were oered to the antibodies and bound phage were detected by HRP-labelled sheep anti-M13 antibodies (Pharmacia). For detection of MDMX expressing phage rabbit anti-MDMX antiserum (1 : 500) was used which had been captured to the wells with anti-rabbit antibodies (Dako Z421). All dilutions were made in blocking buer (PBS, 0.1% Tween20 and 5% low-fat milk powder) and washings between the incubation steps were done with tap water.
Peptide-based ELISA (Figure 2 ) Phage were added to wells containing biotinylated peptides (500 nM) bound to streptavidin (coating concentration 5 mg/ml; (BoÈ ttger et al., 1997a) . Captured phage were detected as described above.
p53 ELISA (Figure 3b ): Plates were coated with decreasing concentrations of p53 (0.01-1000 nM in PBS), blocked with blocking buer and incubated with GSTmdm2 (1 ± 188) or GST-MDMX (1 ± 185) at 40 nM. A rabbit anti-GST antiserum was added to the wells followed by HRP-labelled anti-rabbit antibodies (Dako P217). The HRP activity was measured with TMB/H 2 O 2 .
Peptide ELISA (Figure 3a ): Decreasing concentration of biotinylated peptides (0.1 ± 10000 nM) were bound to streptavidin coated plates. Binding of added GST-mdm2 or GST-MDMX (40 nM) was monitored as described above.
Inhibition ELISAs:
Inhibition of p53 ELISA (Table 1, Figure 3c and 6b ± f) ELISA plates were coated with 20 nM p53. GSTmdm2 or GST-MDMX (40 nM) or antibodies to p53 were preincubated with a dilution series of p53-or phagederived peptides or SuperTip protein (Figure 3c ) and the mixture was added to the p53 coated wells. GST fusion proteins and monoclonal antibodies bound to p53 were detected with rabbit anti-GST/HRP-anti-rabbit or HRPanti-mouse antibodies. The peptide concentration causing 50% inhibition of mdm2 or MDMX binding to p53 was calculated end is expressed as IC 50 in Table 1 .
Inhibition of peptide ELISA (Figure 6a ) A biotinylated p53 wildtype peptide comprising the binding sequence for mdm2 on p53 (BoÈ ttger et al., 1997a) was immobilized on streptavidin. GST-mdm2 was preincubated with an amino acid replacement series of a p53 peptide optimized for mdm2 binding (wt_CON, see Table 1 ) and then added to the peptide plate. Mdm2 binding was determined with monoclonal anti-mdm2 antibody SMP14 followed by HRP-labelled anti-mouse antibodies (Dako P260).
BIAcore analysis
Experiment 1 (Figure 4a and b) : 30 ml biotinylated phagederived peptides 12/1 and 12/5, or p53 wildtype peptide (wt), or a negative control peptide (25 nM each in HBS buer: 10 mM HEPES pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005% Surfactant 20) were bound individually to the streptavidin surface of one of the four¯ow channels of a Sensor Chip SA (BIAcore AB, Sweden) at a¯ow rate of 5 ml/min. 30 ml analyte (400 nM GST-mdm2_1 ± 188 or GST-MDMX_1 ± 185) was then injected at a constant¯ow rate of 5 ml/min. HBS at 5 ml/min was used as running buer.
Experiment 2 (Figure 4c and d) as experiment 1 with following modi®cations: peptide concentration 250 nM (ligand); protein concentration 500 nM (analyte); injection volume analyte 50 ml; The sensorgrams were analysed using BIAevaluation 3.0 software.
Binding assay with in vitro translated p53 ( Figure 5) Approximately 1 mg bacterially produced, full-length human GST-MDMX (Shvarts et al., 1997) or GST-mdm2 (kindly provided by SM Picksley), coupled to glutathione sepharose 4B beads (Pharmacia Biotech) was incubated in the absence or in the presence of either 0.1, 1, 10, 50 or 100 mM mdm2 binding peptide in 100 ml NETN buer containing protease inhibitors (100 mM NaCl, 0.5% NP-40, 50 mM Tris-HCl pH 7.0, 5 mM EDTA pH 8.0, 1 mM PMSF, 1 mg/ml trypsine inhibitor) for 15 min on ice. Peptides used were either wt, wt-CON, 12/5 or BB3. Subsequently, 2 ml in vitro translated, 35 S-labelled-p53 protein (TNT kit, Promega), diluted in 25 ml NETN with protease inhibitors, was added to the preincubation mixture and tumbled for 1 h at 48C. After this incubation the beads were washed three times with NETN, and complexes were separated on a 8% SDS-polyacrylamide gel. Gels were prepared for¯uorography with 22.6% PPO (2,5-diphenyloxazole) in dimethylsulphoxide, dried and exposed to XAR-5 ®lm (KODAK) at 7808C for autoradiography, and to a PhosphorImager screen which was analysed by B&L systems Molecular Dynamics software. Values obtained were plotted in a graph to determine IC 50 values (peptide concentration, required to reduce the association between p53 and either MDMX or mdm2 to 50%, given in mM).
Peptides and Antibodies
Peptides Biotinylated peptides used for this study were synthesized in the format: Bio-SGSG-peptide-NH 2 (Novartis) . Their sequences are shown in Table 1 . Peptides 84 and 90 ( Figure 2 ) were used as negative controls. They cover amino acid sequence 61 ± 80 and 151 ± 170, respectively, of human mdm2 (BoÈ ttger et al., 1997a) .
The peptides of the amino acid replacement series have the format: Ac-peptide-NH 2 (Chiron).
Phosphopeptides 18mer peptides were synthesized which cover the amino acid sequence 10 ± 27 of wildtype p53 containing the mdm2 binding site on p53. The peptides are biotinylated and have phosphoserine or phosphothreonine incorporated at the following position(s): S15; T18; S20; without. The peptides were synthesised manually using previously described protocols (Garcia-Echeverria, 1995a,b) . The purity of the ®nal compounds was veri®ed by reversed-phase analytical HPLC, and the identity was assessed by correct mass spectral analyses. Quantitative amino acid analyses of the puri®ed peptides after acid hydrolysis gave the expected composition.
Antibodies anti-mdm2: 4B2 and 3G5 (Chen et al., 1993) ; SMP14 (Picksley et al., 1994) ; S1/8 and CT12 (BoÈ ttger unpublished); anti-c-myc: 9E10 (Chan et al., 1987) ; antiphage pVIII: FE2 (Micheel et al., 1994) ; anti-p53: DO-1 and DO-2 (Vojtesek et al., 1992) ; Bp53.19 (Bartek et al., 1993) ; Rabbit anti-MDMX (Ramos et al. unpublished) 
